Project Grant R43CA285143
Award Date
9/15/23
Completion Date
8/31/24
Dollars Obligated
$276K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $275,396 to Link Biosystems Inc., a self-certified small disadvantaged business, to develop bioreactor technologies for efficient differentiation, scale-up, and maturation of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. The research aims to address challenges in producing clinically relevant quantities of...
This $353,204 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports the development of a novel technology called Cell-MAPP by Pumpkinseed Technologies Inc., a for-profit company located in Palo Alto, California. The goal of this Phase I Small Business Innovation Research (SBIR) project is to demonstrate and advance Cell-MAPP, a live-cell monitoring system that enables continuous, high-throughput analysis of T cell states...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...
The National Science Foundation (NSF) awarded a $1,213,619 Cooperative Agreement under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Encapsulate Inc., a small disadvantaged business in Farmington, CT. This Phase II Small Business Innovation Research (SBIR) project aims to develop a precision oncology platform that integrates microfluidics, biochips, bioreactors, and 3D tumor models to predict patient-specific cancer drug responses. The proposed technology utilizes...
The National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), awarded a $404,994 Project Grant (CFDA 93.396 - Cancer Biology Research) to Aperture Bio, Inc., a woman-owned small business in Cambridge, MA. The objective of this 1-year grant, with a start date of March 1, 2025, is to determine the feasibility of using Aperture Bio's platform for preclinical drug development applications in organoids, as well as process development and research applications in cell...
The National Cancer Institute (NCI) has awarded a $554,653 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Institute for Systems Biology (ISB) in Seattle, WA. The 4-year grant titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES" aims to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs)...
Rattan Life Science Inc. received a $275,000 Project Grant award from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a platform for generating induced pluripotent stem cell-derived naïve CD4+ and CD8+ T cells with fidelity, reproducibility and scalability. The platform employs proprietary induced thymic epithelial cells to provide biologically relevant thymic positive selection signals during T cell differentiation,...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) grant of $305,000 awarded to Redpoint Oncology, Inc. aims to develop and validate a novel platform for targeted cancer therapies. The project seeks to design and synthesize new therapeutic payloads that can selectively target and destroy therapy-resistant cancer cells. Research objectives include testing the effectiveness and selectivity of the payload...
This Cooperative Agreement award from the National Science Foundation (NSF), under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program, provides $1,250,000 in funding to Rattan Life Science Inc., a self-certified small disadvantaged business, for the development and validation of a novel platform technology to enable the scalable generation of high-quality, tumor-targeted induced naïve T cells for off-the-shelf cancer immunotherapies. The project aims to increase the...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Technology Transfer (STTR) project grant, awarded to Vivosphere LLC, is developing a novel 3D tissue-engineered platform for cancer modeling and high-throughput drug screening. The $275,000 project aims to create a more physiologically relevant and scalable system to improve the translation of preclinical cancer drug candidates to clinical trials. Key objectives include testing...